We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Evaluates Cost-Effectiveness of Hemophilia Gene Therapies, ALS Drugs
ICER Evaluates Cost-Effectiveness of Hemophilia Gene Therapies, ALS Drugs
In a pair of new reports, nonprofit research group the Institute for Clinical and Economic Review (ICER) assessed the cost benefit analyses for oral therapies treating amyotrophic lateral sclerosis (ALS) and gene therapies for use against hemophilia.